Product image of Egoropal (Paliperidone Palmitate) supplied by GNH India

Egoropal

Active Ingredient:
Paliperidone Palmitate
Origin:
EU

Egoropal (Paliperidone Palmitate)

Egoropal is a pharmaceutical product containing Paliperidone Palmitate, used for intramuscular administration. It is manufactured by Egis Pharmaceuticals Plc and is available in the EU market.

Manufacturer / TM Owner

Egis Pharmaceuticals Plc

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Egoropal is primarily used for the treatment of schizophrenia in adults. Paliperidone Palmitate, the active ingredient, is designed to provide long-acting relief and is administered via intramuscular injection. This medication is often prescribed to help manage symptoms associated with schizophrenia, offering a convenient and effective treatment option.

Side Effects

  • Common effects of Egoropal may include injection site reactions, weight gain, and changes in metabolism. Some individuals might experience drowsiness, dizziness, or gastrointestinal discomfort. It is important to monitor for any unusual symptoms and consult a healthcare provider if concerns arise.

Precautions & Warnings

  • Egoropal should be handled with care, ensuring proper storage and administration by trained professionals. It is crucial to follow the prescribed dosage and schedule to minimize potential side effects. Patients with a history of certain medical conditions should discuss their health status with a healthcare provider before starting this medication.

Avoid Interactions

  • Egoropal may interact with other medications, including those that affect the central nervous system. Alcohol and certain supplements can also influence its effectiveness. It is advisable to inform healthcare providers about all current medications to avoid potential interactions.

Frequently Asked Questions

Egoropal is used for the treatment of schizophrenia in adults, providing long-acting relief through intramuscular administration.

Egoropal is administered via intramuscular injection, typically by a healthcare professional.

Common side effects may include injection site reactions, weight gain, drowsiness, and gastrointestinal discomfort.

Egoropal may interact with other medications, so it is important to consult a healthcare provider before combining it with other treatments.

Egoropal is manufactured by Egis Pharmaceuticals Plc, a company based in the EU.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Paliperidone Palmitate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT